{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T06:49:15Z","timestamp":1745390955382,"version":"3.37.3"},"reference-count":220,"publisher":"Bentham Science Publishers Ltd.","issue":"30","funder":[{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e Tecnologia","doi-asserted-by":"publisher","award":["UIDB 50006\/2020"],"award-info":[{"award-number":["UIDB 50006\/2020"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CPD"],"published-print":{"date-parts":[[2020,9,4]]},"abstract":"<jats:sec><jats:title\/><jats:p>The endothelium has a crucial role in proper hemodynamics. Inflammatory bowel disease (IBD) is mainly a chronic inflammatory condition of the gastrointestinal tract. However, considerable evidence points to high cardiovascular risk in patients with IBD. This review positions the basic mechanisms of endothelial dysfunction in the IBD setting (both clinical and experimental). Furthermore, we review the main effects of drugs used to treat IBD in endothelial (dys)function. Moreover, we leave challenging points for enlarging the therapeutic arsenal for IBD with new or repurposed drugs that target endothelial dysfunction besides inflammation.<\/jats:p><\/jats:sec>","DOI":"10.2174\/1381612826666200701212414","type":"journal-article","created":{"date-parts":[[2020,7,2]],"date-time":"2020-07-02T05:00:15Z","timestamp":1593666015000},"page":"3733-3747","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Experimental and Clinical Evidence of Endothelial Dysfunction in Inflammatory Bowel Disease"],"prefix":"10.2174","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7875-8351","authenticated-orcid":true,"given":"Mariana","family":"Ferreira-Duarte","sequence":"first","affiliation":[{"name":"LAQV@REQUIMTE, University of Porto, Porto, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1744-7840","authenticated-orcid":true,"given":"Joana Beatriz","family":"Sousa","sequence":"additional","affiliation":[{"name":"LAQV@REQUIMTE, University of Porto, Porto, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4668-9360","authenticated-orcid":true,"given":"Carmen","family":"Diniz","sequence":"additional","affiliation":[{"name":"LAQV@REQUIMTE, University of Porto, Porto, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7230-5020","authenticated-orcid":true,"given":"Teresa","family":"Sousa","sequence":"additional","affiliation":[{"name":"Department of Biomedicine, Unit of Pharmacology and Therapeutics, Faculty of Medicine, University of Porto, Porto, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4727-727X","authenticated-orcid":true,"given":"Margarida","family":"Duarte-Ara\u00fajo","sequence":"additional","affiliation":[{"name":"LAQV@REQUIMTE, University of Porto, Porto, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9509-0613","authenticated-orcid":true,"given":"Manuela","family":"Morato","sequence":"additional","affiliation":[{"name":"LAQV@REQUIMTE, University of Porto, Porto, Portugal"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3390\/jcm7110400","volume":"7","author":"Bermejo-Martin J.F.","year":"2018","unstructured":"Bermejo-Martin J.F.; Mart\u00edn-Fernandez M.; L\u00f3pez-Mestanza C.; Duque P.; Almansa R.; Shared features of endothelial dysfunction between sepsis and its preceding risk factors (Aging and Chronic Disease). J Clin Med 2018,7(11),7","journal-title":"J Clin Med"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1111\/apha.12860","volume":"222","author":"Radeva M.Y.","year":"2018","unstructured":"Radeva M.Y.; Waschke J.; Mind the gap: mechanisms regulating the endothelial barrier. Acta Physiol (Oxf) 2018,222(1),222","journal-title":"Acta Physiol (Oxf)"},{"key":"ref=3","doi-asserted-by":"publisher","DOI":"10.1155\/2016\/3758278","volume":"2016","author":"Martin L.","year":"2016","unstructured":"Martin L.; Koczera P.; Zechendorf E.; Schuerholz T.; the endothelial glycocalyx: new diagnostic and therapeutic approaches in sepsis. BioMed Res Int 2016,2016","journal-title":"BioMed Res Int"},{"key":"ref=4","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/694312","volume":"2014","author":"Kol\u00e1\u0159ov\u00e1 H.","year":"2014","unstructured":"Kol\u00e1\u0159ov\u00e1 H.; Ambr\u016fzov\u00e1 B.; Svih\u00e1lkov\u00e1 \u0160indlerov\u00e1 L.; Klinke A.; Kubala L.; Modulation of endothelial glycocalyx structure under inflammatory conditions. Mediators Inflamm 2014,2014","journal-title":"Mediators Inflamm"},{"key":"ref=5","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.tips.2017.01.008","volume":"38","author":"McCarron J.G.","year":"2017","unstructured":"McCarron J.G.; Lee M.D.; Wilson C.; The Endothelium Solves Problems That Endothelial Cells Do Not Know Exist. Trends Pharmacol Sci 2017,38,322-338","journal-title":"Trends Pharmacol Sci"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.7150\/ijbs.7502","volume":"9","author":"Rajendran P.","year":"2013","unstructured":"Rajendran P.; Rengarajan T.; Thangavel J.; The vascular endothelium and human diseases. Int J Biol Sci 2013,9(10),1057-1069","journal-title":"Int J Biol Sci"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1002\/jcb.240460106","volume":"46","author":"Rubanyi G.M.","year":"1991","unstructured":"Rubanyi G.M.; Endothelium-derived relaxing and contracting factors. J Cell Biochem 1991,46(1),27-36","journal-title":"J Cell Biochem"},{"year":"2017","author":"Joana Sousa CD","key":"ref=8","unstructured":"Joana Sousa CD; Vascular Sysmpathetic Neurotransmission and endothelial dysfunction. Endothelial dysfunction - old concepts and new challenges2017"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1016\/j.cardiores.2004.10.007","volume":"65","author":"Somoza B.","year":"2005","unstructured":"Somoza B.; Gonz\u00e1lez M.C.; Gonz\u00e1lez J.M.; Abderrahim F.; Arribas S.M.; Fern\u00e1ndez-Alfonso M.S.; Modulatory role of the adventitia on noradrenaline and angiotensin II responses role of endothelium and AT2 receptors. Cardiovasc Res 2005,65(2),478-486","journal-title":"Cardiovasc Res"},{"key":"ref=10","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0129224","volume":"10","author":"Sousa J.B.","year":"2015","unstructured":"Sousa J.B.; Vieira-Rocha M.S.; Arribas S.M.; Gonz\u00e1lez M.C.; Fresco P.; Diniz C.; Endothelial and neuronal nitric oxide activate distinct pathways on sympathetic neurotransmission in rat tail and mesenteric arteries. PLoS One 2015,10(6)","journal-title":"PLoS One"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.neuint.2014.11.001","volume":"80","author":"Sousa J.B.","year":"2015","unstructured":"Sousa J.B.; Fresco P.; Diniz C.; Endothelial dysfunction impairs vascular neurotransmission in tail arteries. Neurochem Int 2015,80,7-13","journal-title":"Neurochem Int"},{"key":"ref=12","first-page":"109","volume":"43","author":"Moncada S.","year":"1991","unstructured":"Moncada S.; Palmer R.M.; Higgs E.A.; Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol Rev 1991,43(2),109-142","journal-title":"Pharmacol Rev"},{"key":"ref=13","doi-asserted-by":"crossref","first-page":"813","DOI":"10.33549\/physiolres.931581","volume":"57","author":"T\u00f6r\u00f6k J.","year":"2008","unstructured":"T\u00f6r\u00f6k J.; Participation of nitric oxide in different models of experimental hypertension. Physiol Res 2008,57(6),813-825","journal-title":"Physiol Res"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1253\/circj.CJ-08-1169","volume":"73","author":"Vanhoutte P.M.","year":"2009","unstructured":"Vanhoutte P.M.; Endothelial dysfunction: the first step toward coronary arteriosclerosis. Circ J 2009,73(4),595-601","journal-title":"Circ J"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1111\/j.1748-1716.2009.01964.x","volume":"196","author":"Vanhoutte P.M.","year":"2009","unstructured":"Vanhoutte P.M.; Shimokawa H.; Tang E.H.; Feletou M.; Endothelial dysfunction and vascular disease. Acta Physiol (Oxf) 2009,196(2),193-222","journal-title":"Acta Physiol (Oxf)"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1111\/micc.12035","volume":"20","author":"Westcott E.B.","year":"2013","unstructured":"Westcott E.B.; Segal S.S.; Perivascular innervation: a multiplicity of roles in vasomotor control and myoendothelial signaling. Microcirculation 2013,20(3),217-238","journal-title":"Microcirculation"},{"key":"ref=17","first-page":"H865","volume":"268","author":"Olmos L.","year":"1995","unstructured":"Olmos L.; Mombouli J.V.; Illiano S.; Vanhoutte P.M.; cGMP mediates the desensitization to bradykinin in isolated canine coronary arteries. Am J Physiol 1995,268(2 Pt 2),H865-H870","journal-title":"Am J Physiol"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1097\/00004872-199917100-00001","volume":"17","author":"Fern\u00e1ndez-Alfonso M.S.","year":"1999","unstructured":"Fern\u00e1ndez-Alfonso M.S.; Gonz\u00e1lez C.; Nitric oxide and the reninangiotensin system. Is there a physiological interplay between the systems? J Hypertens 1999,17(10),1355-1361","journal-title":"J Hypertens"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1161\/HYPERTENSIONAHA.109.129973","volume":"54","author":"Facemire C.S.","year":"2009","unstructured":"Facemire C.S.; Nixon A.B.; Griffiths R.; Hurwitz H.; Coffman T.M.; Vascular endothelial growth factor receptor 2 controls blood pressure by regulating nitric oxide synthase expression. Hypertension 2009,54(3),652-658","journal-title":"Hypertension"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1093\/cvr\/cvr267","volume":"93","author":"Hou H.H.","year":"2012","unstructured":"Hou H.H.; Hammock B.D.; Su K.H.; N-terminal domain of soluble epoxide hydrolase negatively regulates the VEGF-mediated activation of endothelial nitric oxide synthase. Cardiovasc Res 2012,93(1),120-129","journal-title":"Cardiovasc Res"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"2308","DOI":"10.1111\/bph.12559","volume":"171","author":"Skinner M.","year":"2014","unstructured":"Skinner M.; Philp K.; Lengel D.; The contribution of VEGF signalling to fostamatinib-induced blood pressure elevation. Br J Pharmacol 2014,171(9),2308-2320","journal-title":"Br J Pharmacol"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"H985","DOI":"10.1152\/ajpheart.00292.2006","volume":"291","author":"F\u00e9l\u00e9tou M.","year":"2006","unstructured":"F\u00e9l\u00e9tou M.; Vanhoutte P.M.; Endothelial dysfunction: a multifaceted disorder (The Wiggers Award Lecture). Am J Physiol Heart Circ Physiol 2006,291(3),H985-H1002","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"e218","DOI":"10.1055\/s-0038-1660505","volume":"2","author":"van der Vorm L.N.","year":"2018","unstructured":"van der Vorm L.N.; Remijn J.A.; de Laat B.; Huskens D.; Effects of Plasmin on von Willebrand Factor and Platelets: A Narrative Review. TH Open 2018,2(2),e218-e228","journal-title":"TH Open"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1161\/HYPERTENSIONAHA.111.182220","volume":"59","author":"Kappers M.H.","year":"2012","unstructured":"Kappers M.H.; de Beer V.J.; Zhou Z.; Sunitinib-induced systemic vasoconstriction in swine is endothelin mediated and does not involve nitric oxide or oxidative stress. Hypertension 2012,59(1),151-157","journal-title":"Hypertension"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1089\/ars.2013.5244","volume":"20","author":"Lankhorst S.","year":"2014","unstructured":"Lankhorst S.; Kappers M.H.; van Esch J.H.; Danser A.H.; van den Meiracker A.H.; Hypertension during vascular endothelial growth factor inhibition: focus on nitric oxide, endothelin-1, and oxidative stress. Antioxid Redox Signal 2014,20(1),135-145","journal-title":"Antioxid Redox Signal"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1007\/5584_2016_90","volume":"956","author":"Konukoglu D.","year":"2017","unstructured":"Konukoglu D.; Uzun H.; Endothelial dysfunction and hypertension. Adv Exp Med Biol 2017,956,511-540","journal-title":"Adv Exp Med Biol"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1080\/pdp.21.3.279.290","volume":"21","author":"Gryglewski R.J.","year":"2002","unstructured":"Gryglewski R.J.; Uracz W.; Ch\u0142opicki S.; Marcinkiewicz E.; Bradykinin as a major endogenous regulator of endothelial function. Pediatr Pathol Mol Med 2002,21(3),279-290","journal-title":"Pediatr Pathol Mol Med"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/S0033-0620(96)80003-X","volume":"39","author":"Vanhoutte P.M.","year":"1996","unstructured":"Vanhoutte P.M.; Mombouli J.V.; Vascular endothelium: vasoactive mediators. Prog Cardiovasc Dis 1996,39(3),229-238","journal-title":"Prog Cardiovasc Dis"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1152\/physrev.00036.2017","volume":"99","author":"Tejero J.","year":"2019","unstructured":"Tejero J.; Shiva S.; Gladwin M.T.; sources of vascular nitric oxide and reactive oxygen species and their regulation. Physiol Rev 2019,99(1),311-379","journal-title":"Physiol Rev"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1007\/s11906-014-0463-7","volume":"16","author":"Rojas E.","year":"2014","unstructured":"Rojas E.; Rodr\u00edguez-Molina D.; Bolli P.; The role of adiponectin in endothelial dysfunction and hypertension. Curr Hypertens Rep 2014,16(8),463","journal-title":"Curr Hypertens Rep"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1016\/j.freeradbiomed.2009.07.024","volume":"47","author":"V\u00e1squez-Vivar J.","year":"2009","unstructured":"V\u00e1squez-Vivar J.; Tetrahydrobiopterin, superoxide, and vascular dysfunction. Free Radic Biol Med 2009,47(8),1108-1119","journal-title":"Free Radic Biol Med"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1182\/blood-2013-09-512749","volume":"123","author":"Kim Y.W.","year":"2014","unstructured":"Kim Y.W.; Byzova T.V.; Oxidative stress in angiogenesis and vascular disease. Blood 2014,123(5),625-631","journal-title":"Blood"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.2337\/diabetes.54.6.1615","volume":"54","author":"Brownlee M.","year":"2005","unstructured":"Brownlee M.; The pathobiology of diabetic complications: a unifying mechanism. Diabetes 2005,54(6),1615-1625","journal-title":"Diabetes"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1111\/jth.12225","volume":"11","author":"Nightingale T.","year":"2013","unstructured":"Nightingale T.; Cutler D.; The secretion of von Willebrand factor from endothelial cells; an increasingly complicated story. J Thromb Haemost 2013,11(Suppl. 1),192-201","journal-title":"J Thromb Haemost"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"82","DOI":"10.2174\/157340310791162659","volume":"6","author":"Sibal L.","year":"2010","unstructured":"Sibal L.; Agarwal S.C.; Home P.D.; Boger R.H.; The role of asymmetric dimethylarginine (adma) in endothelial dysfunction and cardiovascular disease. Curr Cardiol Rev 2010,6(2),82-90","journal-title":"Curr Cardiol Rev"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1172\/JCI66843","volume":"123","author":"Liao J.K.","year":"2013","unstructured":"Liao J.K.; Linking endothelial dysfunction with endothelial cell activation. J Clin Invest 2013,123(2),540-541","journal-title":"J Clin Invest"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1002\/jcp.24485","volume":"229","author":"Lee W.","year":"2014","unstructured":"Lee W.; Ku S.K.; Kim S.W.; Bae J.S.; Endocan elicits severe vascular inflammatory responses in vitro and in vivo. J Cell Physiol 2014,229(5),620-630","journal-title":"J Cell Physiol"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"3099","DOI":"10.4049\/jimmunol.167.6.3099","volume":"167","author":"B\u00e9chard D.","year":"2001","unstructured":"B\u00e9chard D.; Scherpereel A.; Hammad H.; Human endothelial-cell specific molecule-1 binds directly to the integrin CD11a\/CD18 (LFA-1) and blocks binding to intercellular adhesion molecule-1. J Immunol 2001,167(6),3099-3106","journal-title":"J Immunol"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1038\/nature09599","volume":"468","author":"Chen C.A.","year":"2010","unstructured":"Chen C.A.; Wang T.Y.; Varadharaj S.; S-glutathionylation uncouples eNOS and regulates its cellular and vascular function. Nature 2010,468(7327),1115-1118","journal-title":"Nature"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1111\/bph.13517","volume":"174","author":"Daiber A.","year":"2017","unstructured":"Daiber A.; Steven S.; Weber A.; Targeting vascular (endothelial) dysfunction. Br J Pharmacol 2017,174(12),1591-1619","journal-title":"Br J Pharmacol"},{"key":"ref=41","author":"Luz P.L.D.","year":"2018","unstructured":"Luz P.L.D.; Libby P.; Chagas A.C.P.; Laurindo F.R.M.; Endothelium and cardiovascular diseases vascular biology and clinical syndromes 2018","journal-title":"Endothelium and cardiovascular diseases vascular biology and clinical syndromes"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1002\/ibd.20994","volume":"16","author":"Owczarek D.","year":"2010","unstructured":"Owczarek D.; Cibor D.; Mach T.; Asymmetric dimethylarginine (ADMA), symmetric dimethylarginine (SDMA), arginine, and 8- iso-prostaglandin F2alpha (8-iso-PGF2alpha) level in patients with inflammatory bowel diseases. Inflamm Bowel Dis 2010,16(1),52-57","journal-title":"Inflamm Bowel Dis"},{"key":"ref=43","first-page":"509","author":"R.- C.M.","year":"2019","unstructured":"R.- C.M.; Sousa T.; Gomes P.; Oxidative Stress in Heart Diseases DN Chakraborti S, Ganguly N, Dikshit M (Ed)2019,509-37","journal-title":"Oxidative Stress in Heart Diseases"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1016\/j.autrev.2017.07.008","volume":"16","author":"Al-Soudi A.","year":"2017","unstructured":"Al-Soudi A.; Kaaij M.H.; Tas S.W.; Endothelial cells: From innocent bystanders to active participants in immune responses. Autoimmun Rev 2017,16(9),951-962","journal-title":"Autoimmun Rev"},{"year":"2010","key":"ref=45","unstructured":"R.R.; Yuan SY; Sciences MCL. Ed.2010"},{"key":"ref=46","first-page":"244","author":"G.D. Kvietysvi P.","year":"2014","unstructured":"G.D. Kvietysvi P.; Mediators and mechanisms of the in-creased blood flow, vascular permeability, and blood vessel proliferation in inflamed tissue. Pathobiology of Human Disease MR McManus LM (Ed)2014,244-57","journal-title":"Pathobiology of Human Disease"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"1815","DOI":"10.1111\/j.1538-7836.2005.01378.x","volume":"3","author":"Winn R.K.","year":"2005","unstructured":"Winn R.K.; Harlan J.M.; The role of endothelial cell apoptosis in inflammatory and immune diseases. J Thromb Haemost 2005,3(8),1815-1824","journal-title":"J Thromb Haemost"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1007\/978-3-319-57613-8_4","volume":"1003","author":"Sturtzel C.","year":"2017","unstructured":"Sturtzel C.; Endothelial cells. Adv Exp Med Biol 2017,1003,71-91","journal-title":"Adv Exp Med Biol"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1038\/ncprheum0647","volume":"3","author":"Szekanecz Z.","year":"2007","unstructured":"Szekanecz Z.; Koch A.E.; Mechanisms of disease: angiogenesis in inflammatory diseases. Nat Clin Pract Rheumatol 2007,3(11),635-643","journal-title":"Nat Clin Pract Rheumatol"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"578","DOI":"10.3748\/wjg.v17.i5.578","volume":"17","author":"Cromer W.E.","year":"2011","unstructured":"Cromer W.E.; Mathis J.M.; Granger D.N.; Chaitanya G.V.; Alexander J.S.; Role of the endothelium in inflammatory bowel diseases. World J Gastroenterol 2011,17(5),578-593","journal-title":"World J Gastroenterol"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1089\/ars.2007.1998","volume":"10","author":"Watson T.","year":"2008","unstructured":"Watson T.; Goon P.K.; Lip G.Y.; Endothelial progenitor cells, endothelial dysfunction, inflammation, and oxidative stress in hypertension. Antioxid Redox Signal 2008,10(6),1079-1088","journal-title":"Antioxid Redox Signal"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"459","DOI":"10.18388\/abp.2004_3584","volume":"51","author":"Kalinowski L.","year":"2004","unstructured":"Kalinowski L.; Malinski T.; Endothelial NADH\/NADPH-dependent enzymatic sources of superoxide production: relationship to endothelial dysfunction. Acta Biochim Pol 2004,51(2),459-469","journal-title":"Acta Biochim Pol"},{"key":"ref=53","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/845037","volume":"2013","author":"Lin C.P.","year":"2013","unstructured":"Lin C.P.; Lin F.Y.; Huang P.H.; Endothelial progenitor cell dysfunction in cardiovascular diseases: role of reactive oxygen species and inflammation. BioMed Res Int 2013,2013","journal-title":"BioMed Res Int"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1056\/NEJMoa043814","volume":"353","author":"Werner N.","year":"2005","unstructured":"Werner N.; Kosiol S.; Schiegl T.; Circulating endothelial progenitor cells and cardiovascular outcomes. N Engl J Med 2005,353(10),999-1007","journal-title":"N Engl J Med"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1056\/NEJMoa022287","volume":"348","author":"Hill J.M.","year":"2003","unstructured":"Hill J.M.; Zalos G.; Halcox J.P.; Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. N Engl J Med 2003,348(7),593-600","journal-title":"N Engl J Med"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"11324","DOI":"10.3390\/ijms150711324","volume":"15","author":"Steyers C.M.","year":"2014","unstructured":"Steyers C.M.; Miller F.J.; Endothelial dysfunction in chronic inflammatory diseases. Int J Mol Sci 2014,15(7),11324-11349","journal-title":"Int J Mol Sci"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1179\/acb.2006.036","volume":"61","author":"Verhamme P.","year":"2006","unstructured":"Verhamme P.; Hoylaerts M.F.; The pivotal role of the endothelium in haemostasis and thrombosis. Acta Clin Belg 2006,61(5),213-219","journal-title":"Acta Clin Belg"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"2769","DOI":"10.1016\/S0140-6736(17)32448-0","volume":"390","author":"Ng S.C.","year":"2018","unstructured":"Ng S.C.; Shi H.Y.; Hamidi N.; Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lancet 2018,390(10114),2769-2778","journal-title":"Lancet"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"2363","DOI":"10.3748\/wjg.v24.i22.2363","volume":"24","author":"Strohl M.","year":"2018","unstructured":"Strohl M.; Gonczi L.; Kurt Z.; Bessissow T.; Lakatos P.L.; Quality of care in inflammatory bowel diseases: What is the best way to better outcomes? World J Gastroenterol 2018,24(22),2363-2372","journal-title":"World J Gastroenterol"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1177\/2050640615577532","volume":"3","author":"Ramos A.","year":"2015","unstructured":"Ramos A.; Calvet X.; Sicilia B.; IBD-related work disability in the community: Prevalence, severity and predictive factors. A cross-sectional study. United European Gastroenterol J 2015,3(4),335-342","journal-title":"United European Gastroenterol J"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1146\/annurev-immunol-030409-101225","volume":"28","author":"Kaser A.","year":"2010","unstructured":"Kaser A.; Zeissig S.; Blumberg R.S.; Inflammatory bowel disease. Annu Rev Immunol 2010,28,573-621","journal-title":"Annu Rev Immunol"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.jcmgh.2017.03.007","volume":"4","author":"Martini E.","year":"2017","unstructured":"Martini E.; Krug S.M.; Siegmund B.; Neurath M.F.; Becker C.; mend your fences: the epithelial barrier and its relationship with mucosal immunity in inflammatory bowel disease. Cell Mol Gastroenterol Hepatol 2017,4(1),33-46","journal-title":"Cell Mol Gastroenterol Hepatol"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.autrev.2013.06.004","volume":"13","author":"Geremia A.","year":"2014","unstructured":"Geremia A.; Biancheri P.; Allan P.; Corazza G.R.; Di Sabatino A.; Innate and adaptive immunity in inflammatory bowel disease. Autoimmun Rev 2014,13(1),3-10","journal-title":"Autoimmun Rev"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1038\/nature10208","volume":"474","author":"Maloy K.J.","year":"2011","unstructured":"Maloy K.J.; Powrie F.; Intestinal homeostasis and its breakdown in inflammatory bowel disease. Nature 2011,474(7351),298-306","journal-title":"Nature"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1097\/01.MIB.0000160772.78951.61","volume":"11","author":"Hatoum O.A.","year":"2005","unstructured":"Hatoum O.A.; Binion D.G.; The vasculature and inflammatory bowel disease: contribution to pathogenesis and clinical pathology. Inflamm Bowel Dis 2005,11(3),304-313","journal-title":"Inflamm Bowel Dis"},{"key":"ref=66","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1097\/CRD.0000000000000214","volume":"26","author":"Nevulis M.G.","year":"2018","unstructured":"Nevulis M.G.; Baker C.; Lebovics E.; Frishman W.H.; Overview of link between inflammatory bowel disease and cardiovascular disease. Cardiol Rev 2018,26,287-293","journal-title":"Cardiol Rev"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1177\/2047487318792952","volume":"25","author":"Sun H.H.","year":"2018","unstructured":"Sun H.H.; Tian F.; Inflammatory bowel disease and cardiovascular disease incidence and mortality: A meta-analysis. Eur J Prev Cardiol 2018,25(15),1623-1631","journal-title":"Eur J Prev Cardiol"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1007\/s00384-015-2132-y","volume":"30","author":"Keller J.J.","year":"2015","unstructured":"Keller J.J.; Wang J.; Hwang Y.L.; Increased risk of stroke among patients with Crohn\u2019s disease: a population-based matched cohort study. Int J Colorectal Dis 2015,30(5),645-653","journal-title":"Int J Colorectal Dis"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1097\/MOG.0b013e32810c8de3","volume":"23","author":"Danese S.","year":"2007","unstructured":"Danese S.; Inflammation and the mucosal microcirculation in inflammatory bowel disease: the ebb and flow. Curr Opin Gastroenterol 2007,23(4),384-389","journal-title":"Curr Opin Gastroenterol"},{"key":"ref=70","first-page":"193","volume":"15","author":"Ma M.Y.","year":"1999","unstructured":"Ma M.Y.; Xu X.H.; Luo B.; Immunohistochemical study on myocardial acute ischemia reperfusion injury in rats with anti-FOS protein antibody. Fa Yi Xue Za Zhi 1999,15,193-195, 254","journal-title":"Fa Yi Xue Za Zhi"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1160\/TH15-09-0710","volume":"115","author":"He Z.","year":"2016","unstructured":"He Z.; Si Y.; Jiang T.; Phosphotidylserine exposure and neutrophil extracellular traps enhance procoagulant activity in patients with inflammatory bowel disease. Thromb Haemost 2016,115(4),738-751","journal-title":"Thromb Haemost"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"1895","DOI":"10.1053\/gast.1997.v112.pm9178682","volume":"112","author":"Binion D.G.","year":"1997","unstructured":"Binion D.G.; West G.A.; Ina K.; Ziats N.P.; Emancipator S.N.; Fiocchi C.; Enhanced leukocyte binding by intestinal microvascular endothelial cells in inflammatory bowel disease. Gastroenterology 1997,112(6),1895-1907","journal-title":"Gastroenterology"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.3748\/wjg.v22.i3.1067","volume":"22","author":"Cibor D.","year":"2016","unstructured":"Cibor D.; Domagala-Rodacka R.; Rodacki T.; Jurczyszyn A.; Mach T.; Owczarek D.; Endothelial dysfunction in inflammatory bowel diseases: Pathogenesis, assessment and implications. World J Gastroenterol 2016,22(3),1067-1077","journal-title":"World J Gastroenterol"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.cgh.2008.10.021","volume":"7","author":"Roifman I.","year":"2009","unstructured":"Roifman I.; Sun Y.C.; Fedwick J.P.; Evidence of endothelial dysfunction in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2009,7(2),175-182","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/S0016-5085(03)00699-1","volume":"125","author":"Hatoum O.A.","year":"2003","unstructured":"Hatoum O.A.; Binion D.G.; Otterson M.F.; Gutterman D.D.; Acquired microvascular dysfunction in inflammatory bowel disease: Loss of nitric oxide-mediated vasodilation. Gastroenterology 2003,125(1),58-69","journal-title":"Gastroenterology"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1097\/01.MIB.0000217764.88980.74","volume":"12","author":"Kocaman O.","year":"2006","unstructured":"Kocaman O.; Sahin T.; Aygun C.; Senturk O.; Hulagu S.; Endothelial dysfunction in patients with ulcerative colitis. Inflamm Bowel Dis 2006,12(3),166-171","journal-title":"Inflamm Bowel Dis"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1016\/j.crohns.2013.09.021","volume":"8","author":"Fumery M.","year":"2014","unstructured":"Fumery M.; Xiaocang C.; Dauchet L.; Gower-Rousseau C.; Peyrin-Biroulet L.; Colombel J.F.; Thromboembolic events and cardiovascular mortality in inflammatory bowel diseases: a meta-analysis of observational studies. J Crohn\u2019s Colitis 2014,8(6),469-479","journal-title":"J Crohn\u2019s Colitis"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1016\/j.tcm.2015.04.001","volume":"25","author":"Zanoli L.","year":"2015","unstructured":"Zanoli L.; Inserra G.; Castellino P.; Increased cardiovascular risk in subjects with a low prevalence of classic cardiovascular risk factors: The inflammatory bowel disease paradox. Trends Cardiovasc Med 2015,25(8),705-706","journal-title":"Trends Cardiovasc Med"},{"key":"ref=79","first-page":"7","volume":"10","author":"Papa A.","year":"2006","unstructured":"Papa A.; Danese S.; Urgesi R.; Early atherosclerosis in patients with inflammatory bowel disease. Eur Rev Med Pharmacol Sci 2006,10(1),7-11","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"ref=80","first-page":"1314","volume":"21","author":"Ozturk K.","year":"2015","unstructured":"Ozturk K.; Guler A.K.; Cakir M.; pulse wave velocity, intima media thickness, and flow-mediated dilatation in patients with normotensive normogly-cemic inflammatory bowel disease. Inflamm Bowel Dis 2015,21,1314-1320","journal-title":"Inflamm Bowel Dis"},{"key":"ref=81","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.jpeds.2012.03.043","volume":"161","author":"Aloi M.","year":"2012","unstructured":"Aloi M.; Tromba L.; Di Nardo G.; Premature subclinical atherosclerosis in pediatric inflammato-ry bowel disease. J Pediatr 2012,161,589-594","journal-title":"J Pediatr"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1097\/MPG.0000000000000771","volume":"61","author":"Aloi M.","year":"2015","unstructured":"Aloi M.; Tromba L.; Rizzo V.; Aortic Intima-media thickness as an early marker of atherosclerosis in children with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2015,61(1),41-46","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1161\/01.CIR.0000048892.83521.58","volume":"107","author":"Lakatta E.G.","year":"2003","unstructured":"Lakatta E.G.; Levy D.; Arterial and cardiac aging: major shareholders in cardiovascular disease enterprises: Part I: aging arteries: a \u201cset up\u201d for vascular disease. Circulation 2003,107(1),139-146","journal-title":"Circulation"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1016\/S0735-1097(01)01108-1","volume":"37","author":"Dart A.M.","year":"2001","unstructured":"Dart A.M.; Kingwell B.A.; Pulse pressure--a review of mechanisms and clinical relevance. J Am Coll Cardiol 2001,37(4),975-984","journal-title":"J Am Coll Cardiol"},{"key":"ref=85","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.vph.2015.11.083","volume":"77","author":"Palombo C.","year":"2016","unstructured":"Palombo C.; Kozakova M.; Arterial stiffness, atherosclerosis and cardiovascular risk: Pathophysiologic mechanisms and emerging clinical indications. Vascul Pharmacol 2016,77,1-7","journal-title":"Vascul Pharmacol"},{"key":"ref=86","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/j.atherosclerosis.2016.04.014","volume":"249","author":"Hansen L.","year":"2016","unstructured":"Hansen L.; Taylor W.R.; Is increased arterial stiffness a cause or consequence of atherosclerosis? Atherosclerosis 2016,249,226-227","journal-title":"Atherosclerosis"},{"key":"ref=87","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1097\/HJH.0000000000000867","volume":"34","author":"Zanoli L.","year":"2016","unstructured":"Zanoli L.; Rastelli S.; Granata A.; Arterial stiffness in inflammatory bowel disease: a systematic review and meta-analysis. J Hypertens 2016,34(5),822-829","journal-title":"J Hypertens"},{"key":"ref=88","doi-asserted-by":"publisher","first-page":"4857","DOI":"10.3748\/wjg.v20.i17.4857","volume":"20","author":"Magro F.","year":"2014","unstructured":"Magro F.; Soares J.B.; Fernandes D.; Venous thrombosis and prothrombotic factors in inflammatory bowel disease. World J Gastroenterol 2014,20(17),4857-4872","journal-title":"World J Gastroenterol"},{"key":"ref=89","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1080\/08037051.2018.1476055","volume":"27","author":"Priji\u0107 R.","year":"2018","unstructured":"Priji\u0107 R.; Premu\u017ei\u0107 V.; Brinar M.; Krznari\u0107 \u017d.; Jelakovi\u0107 B.; \u010cukovi\u0107-\u010cavka S.; Increased arterial stiffness - similar findings in patients with inflammatory bowel disease without prior hypertension or diabetes and in patients with well-controlled hypertension. Blood Press 2018,27(4),240-246","journal-title":"Blood Press"},{"key":"ref=90","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1161\/CIRCRESAHA.115.306301","volume":"118","author":"Gimbrone M.A.","year":"2016","unstructured":"Gimbrone M.A.; Garc\u00eda-Carde\u00f1a G.; endothelial cell dysfunction and the pathobiology of atherosclerosis. Circ Res 2016,118(4),620-636","journal-title":"Circ Res"},{"key":"ref=91","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1056\/NEJMra043430","volume":"352","author":"Hansson G.K.","year":"2005","unstructured":"Hansson G.K.; Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005,352(16),1685-1695","journal-title":"N Engl J Med"},{"key":"ref=92","doi-asserted-by":"publisher","first-page":"290","DOI":"10.2174\/138161209787354221","volume":"15","author":"M\u00e4ki-Pet\u00e4j\u00e4 K.M.","year":"2009","unstructured":"M\u00e4ki-Pet\u00e4j\u00e4 K.M.; Wilkinson I.B.; Anti-inflammatory drugs and statins for arterial stiffness reduction. Curr Pharm Des 2009,15(3),290-303","journal-title":"Curr Pharm Des"},{"key":"ref=93","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s12950-014-0029-0","volume":"11","author":"Fan F.","year":"2014","unstructured":"Fan F.; Galvin A.; Fang L.; Comparison of inflammation, arterial stiffness and traditional cardiovascular risk factors between rheumatoid arthritis and inflammatory bowel disease. J Inflamm (Lond) 2014,11(1),29","journal-title":"J Inflamm (Lond)"},{"key":"ref=94","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1097\/MOG.0b013e328365d37c","volume":"29","author":"D\u2019Alessio S.","year":"2013","unstructured":"D\u2019Alessio S.; Tacconi C.; Fiocchi C.; Danese S.; Advances in therapeutic interventions targeting the vascular and lymphatic endothelium in inflammatory bowel disease. Curr Opin Gastroenterol 2013,29(6),608-613","journal-title":"Curr Opin Gastroenterol"},{"key":"ref=95","doi-asserted-by":"publisher","first-page":"H1791","DOI":"10.1152\/ajpheart.00552.2003","volume":"285","author":"Hatoum O.A.","year":"2003","unstructured":"Hatoum O.A.; Miura H.; Binion D.G.; The vascular contribution in the pathogenesis of inflammatory bowel disease. Am J Physiol Heart Circ Physiol 2003,285(5),H1791-H1796","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"ref=96","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1056\/NEJMra052723","volume":"354","author":"Charo I.F.","year":"2006","unstructured":"Charo I.F.; Ransohoff R.M.; The many roles of chemokines and chemokine receptors in inflammation. N Engl J Med 2006,354(6),610-621","journal-title":"N Engl J Med"},{"key":"ref=97","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1136\/gut.2010.207480","volume":"60","author":"Danese S.","year":"2011","unstructured":"Danese S.; Role of the vascular and lymphatic endothelium in the pathogenesis of inflammatory bowel disease: \u2018brothers in arms\u2019. Gut 2011,60(7),998-1008","journal-title":"Gut"},{"key":"ref=98","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.2353\/ajpath.2008.070593","volume":"172","author":"Deban L.","year":"2008","unstructured":"Deban L.; Correale C.; Vetrano S.; Malesci A.; Danese S.; Multiple pathogenic roles of microvasculature in inflammatory bowel disease: a Jack of all trades. Am J Pathol 2008,172(6),1457-1466","journal-title":"Am J Pathol"},{"key":"ref=99","doi-asserted-by":"publisher","DOI":"10.1155\/2018\/2568569","volume":"2018","author":"Gravina A.G.","year":"2018","unstructured":"Gravina A.G.; Dallio M.; Masarone M.; Vascular endothelial dysfunction in inflammatory bowel diseases: pharmacological and nonpharmacological targets. Oxid Med Cell Longev 2018,2018","journal-title":"Oxid Med Cell Longev"},{"key":"ref=100","doi-asserted-by":"publisher","first-page":"G734","DOI":"10.1152\/ajpgi.2000.278.5.G734","volume":"278","author":"Kawachi S.","year":"2000","unstructured":"Kawachi S.; Jennings S.; Panes J.; Cytokine and endothelial cell adhesion molecule expression in interleukin-10-deficient mice. Am J Physiol Gastrointest Liver Physiol 2000,278(5),G734-G743","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"ref=101","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1097\/00042737-200101000-00006","volume":"13","author":"Sans M.","year":"2001","unstructured":"Sans M.; Fuster D.; V\u00e1zquez A.; 123Iodine-labelled anti-VCAM-1 antibody scintigraphy in the assessment of experimental colitis. Eur J Gastroenterol Hepatol 2001,13(1),31-38","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"ref=102","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1038\/labinvest.3780164","volume":"80","author":"Soriano A.","year":"2000","unstructured":"Soriano A.; Salas A.; Salas A.; VCAM-1, but not ICAM-1 or MAdCAM-1, immunoblockade ameliorates DSS-induced colitis in mice. Lab Invest 2000,80(10),1541-1551","journal-title":"Lab Invest"},{"key":"ref=103","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1111\/cei.13226","volume":"195","author":"Therrien A.","year":"2019","unstructured":"Therrien A.; Chapuy L.; Bsat M.; Recruitment of activated neutrophils correlates with disease severity in adult Crohn\u2019s disease. Clin Exp Immunol 2019,195(2),251-264","journal-title":"Clin Exp Immunol"},{"key":"ref=104","first-page":"97","volume":"151","author":"Briskin M.","year":"1997","unstructured":"Briskin M.; Shyjan A.; Cochran N.; Human mucosal addressin cell adhesion molecule-1 is preferentially expressed in intestinal tract and associated lymphoid tissue. Am J Pathol 1997,151,97-110","journal-title":"Am J Pathol"},{"key":"ref=105","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1016\/0016-5085(95)90560-X","volume":"109","author":"Burgio V.L.","year":"1995","unstructured":"Burgio V.L.; Fais S.; Boirivant M.; Perrone A.; Pallone F.; Peripheral monocyte and naive T-cell recruitment and activation in Crohn\u2019s disease. Gastroenterology 1995,109(4),1029-1038","journal-title":"Gastroenterology"},{"key":"ref=106","doi-asserted-by":"publisher","first-page":"1868","DOI":"10.3748\/wjg.v24.i17.1868","volume":"24","author":"Park S.C.","year":"2018","unstructured":"Park S.C.; Jeen Y.T.; Anti-integrin therapy for inflammatory bowel disease. World J Gastroenterol 2018,24(17),1868-1880","journal-title":"World J Gastroenterol"},{"key":"ref=107","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006097.pub3","volume":"8","author":"Nelson S.M.","year":"2018","unstructured":"Nelson S.M.; Nguyen T.M.; McDonald J.W.; MacDonald J.K.; Natalizumab for induction of remission in Crohn\u2019s disease. Cochrane Database Syst Rev 2018,8","journal-title":"Cochrane Database Syst Rev"},{"key":"ref=108","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1080\/14712598.2020.1691520","volume":"20","author":"Picardo S.","year":"2019","unstructured":"Picardo S.; Panaccione R.; Anti-MADCAM therapy for ulcerative colitis. Expert Opin Biol Ther 2019,20(4),437-442","journal-title":"Expert Opin Biol Ther"},{"key":"ref=109","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/j.jcmgh.2019.10.012","volume":"9","author":"Sun H.","year":"2020","unstructured":"Sun H.; Kuk W.; Rivera-Nieves J.; Lopez-Ramirez M.A.; Eckmann L.; Ginsberg M.H.; \u03b27 integrin inhibition can increase intestinal inflammation by impairing homing of CD25hiFoxP3+ regulatory t cells. Cell Mol Gastroenterol Hepatol 2020,9(3),369-385","journal-title":"Cell Mol Gastroenterol Hepatol"},{"key":"ref=110","doi-asserted-by":"publisher","first-page":"G255","DOI":"10.1152\/ajpgi.00264.2009","volume":"298","author":"Mizushima T.","year":"2010","unstructured":"Mizushima T.; Sasaki M.; Ando T.; Blockage of angiotensin II type 1 receptor regulates TNF-alpha-induced MAdCAM-1 expression via inhibition of NF-kappaB translocation to the nucleus and ameliorates colitis. Am J Physiol Gastrointest Liver Physiol 2010,298(2),G255-G266","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"ref=111","doi-asserted-by":"publisher","first-page":"G1323","DOI":"10.1152\/ajpgi.00499.2006","volume":"292","author":"Horowitz S.","year":"2007","unstructured":"Horowitz S.; Binion D.G.; Nelson V.M.; Increased arginase activity and endothelial dysfunction in human inflammatory bowel disease. Am J Physiol Gastrointest Liver Physiol 2007,292(5),G1323-G1336","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"ref=112","first-page":"H342","volume":"274","author":"Chang C.I.","year":"1998","unstructured":"Chang C.I.; Liao J.C.; Kuo L.; Arginase modulates nitric oxide production in activated macrophages. Am J Physiol 1998,274(1),H342-H348","journal-title":"Am J Physiol"},{"key":"ref=113","doi-asserted-by":"publisher","first-page":"35605","DOI":"10.1074\/jbc.M205826200","volume":"277","author":"Rafiee P.","year":"2002","unstructured":"Rafiee P.; Johnson C.P.; Li M.S.; Cyclosporine A enhances leukocyte binding by human intestinal microvascular endothelial cells through inhibition of p38 MAPK and iNOS. Paradoxical proinflammatory effect on the microvascular endothelium. J Biol Chem 2002,277(38),35605-35615","journal-title":"J Biol Chem"},{"key":"ref=114","first-page":"G592","volume":"275","author":"Binion D.G.","year":"1998","unstructured":"Binion D.G.; Fu S.; Ramanujam K.S.; iNOS expression in human intestinal microvascular endothelial cells inhibits leukocyte adhesion. Am J Physiol 1998,275(3),G592-G603","journal-title":"Am J Physiol"},{"key":"ref=115","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1016\/S0891-5849(00)00391-9","volume":"29","author":"Binion D.G.","year":"2000","unstructured":"Binion D.G.; Rafiee P.; Ramanujam K.S.; Deficient iNOS in inflammatory bowel disease intestinal microvascular endothelial cells results in increased leukocyte adhesion. Free Radic Biol Med 2000,29(9),881-888","journal-title":"Free Radic Biol Med"},{"key":"ref=116","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1016\/S0016-5085(96)70055-0","volume":"111","author":"Singer I.I.","year":"1996","unstructured":"Singer I.I.; Kawka D.W.; Scott S.; Expression of inducible nitric oxide synthase and nitrotyrosine in colonic epithelium in inflammatory bowel disease. Gastroenterology 1996,111(4),871-885","journal-title":"Gastroenterology"},{"key":"ref=117","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1136\/gut.42.2.180","volume":"42","author":"Kimura H.","year":"1998","unstructured":"Kimura H.; Hokari R.; Miura S.; Increased expression of an inducible isoform of nitric oxide synthase and the formation of peroxynitrite in colonic mucosa of patients with active ulcerative colitis. Gut 1998,42(2),180-187","journal-title":"Gut"},{"key":"ref=118","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1515\/BC.2006.190","volume":"387","author":"F\u00f6rstermann U.","year":"2006","unstructured":"F\u00f6rstermann U.; Janus-faced role of endothelial NO synthase in vascular disease: uncoupling of oxygen reduction from NO synthesis and its pharmacological reversal. Biol Chem 2006,387(12),1521-1533","journal-title":"Biol Chem"},{"key":"ref=119","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1177\/039463201102400206","volume":"24","author":"V. Z.","year":"2011","unstructured":"V. Z.; Altorjay I; Serfozo Z; Bacskai I; An-ti-TNF-alpha antibody (infliximab) therapy supports the re-covery of eNOS and VEGFR2 protein expression in endothelial cells. Internation J Immunopathol Pharmacol 2011,24,323-335","journal-title":"Internation J Immunopathol Pharmacol"},{"key":"ref=120","doi-asserted-by":"publisher","first-page":"1679","DOI":"10.1016\/j.freeradbiomed.2003.09.016","volume":"35","author":"Sasaki M.","year":"2003","unstructured":"Sasaki M.; Bharwani S.; Jordan P.; Increased disease activity in eNOS-deficient mice in experimental colitis. Free Radic Biol Med 2003,35(12),1679-1687","journal-title":"Free Radic Biol Med"},{"key":"ref=121","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/1471-230X-1-5","volume":"1","author":"Oshima T.","year":"2001","unstructured":"Oshima T.; Jordan P.; Grisham M.B.; TNF-alpha induced endothelial MAdCAM-1 expression is regulated by exogenous, not endogenous nitric oxide. BMC Gastroenterol 2001,1,5","journal-title":"BMC Gastroenterol"},{"key":"ref=122","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1097\/00054725-200606000-00012","volume":"12","author":"Koutroubakis I.E.","year":"2006","unstructured":"Koutroubakis I.E.; Tsiolakidou G.; Karmiris K.; Kouroumalis E.A.; Role of angiogenesis in inflammatory bowel disease. Inflamm Bowel Dis 2006,12(6),515-523","journal-title":"Inflamm Bowel Dis"},{"key":"ref=123","doi-asserted-by":"publisher","first-page":"249","DOI":"10.2174\/1389203716666150224150756","volume":"16","author":"Eder P.","year":"2015","unstructured":"Eder P.; Korybalska K.; Linke K.; Witowski J.; Angiogenesis-related proteins--their role in the pathogenesis and treatment of inflammatory bowel disease. Curr Protein Pept Sci 2015,16(3),249-258","journal-title":"Curr Protein Pept Sci"},{"key":"ref=124","doi-asserted-by":"publisher","first-page":"2060","DOI":"10.1053\/j.gastro.2006.03.054","volume":"130","author":"Danese S.","year":"2006","unstructured":"Danese S.; Sans M.; de la Motte C.; Angiogenesis as a novel component of inflammatory bowel disease pathogenesis. Gastroenterology 2006,130(7),2060-2073","journal-title":"Gastroenterology"},{"key":"ref=125","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1136\/gut.2006.114314","volume":"56","author":"Danese S.","year":"2007","unstructured":"Danese S.; Sans M.; Spencer D.M.; Angiogenesis blockade as a new therapeutic approach to experimental colitis. Gut 2007,56(6),855-862","journal-title":"Gut"},{"key":"ref=126","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1007\/s11605-015-3002-1","volume":"20","author":"Knod J.L.","year":"2016","unstructured":"Knod J.L.; Crawford K.; Dusing M.; Collins M.H.; Chernoguz A.; Frischer J.S.; Angiogenesis and vascular endothelial growth factor-a expression associated with inflammation in pediatric Crohn\u2019s disease. J Gastrointest Surg 2016,20(3),624-630","journal-title":"J Gastrointest Surg"},{"key":"ref=127","doi-asserted-by":"publisher","first-page":"751","DOI":"10.7863\/jum.1994.13.10.751","volume":"13","author":"Quillin S.P.","year":"1994","unstructured":"Quillin S.P.; Siegel M.J.; Gastrointestinal inflammation in children: color Doppler ultrasonography. J Ultrasound Med 1994,13(10),751-756","journal-title":"J Ultrasound Med"},{"key":"ref=128","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1148\/radiology.217.3.r00dc19787","volume":"217","author":"Spalinger J.","year":"2000","unstructured":"Spalinger J.; Patriquin H.; Miron M.C.; Doppler US in patients with crohn disease: vessel density in the diseased bowel reflects disease activity. Radiology 2000,217(3),787-791","journal-title":"Radiology"},{"key":"ref=129","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1007\/s005350300041","volume":"38","author":"Saito S.","year":"2003","unstructured":"Saito S.; Tsuno N.H.; Sunami E.; Expression of platelet-derived endothelial cell growth factor in inflammatory bowel disease. J Gastroenterol 2003,38(3),229-237","journal-title":"J Gastroenterol"},{"key":"ref=130","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1186\/s12876-019-1037-6","volume":"19","author":"Tian Y.","year":"2019","unstructured":"Tian Y.; Zheng Y.; Teng G.; Li J.; Wang H.; Imbalanced mucosal microcirculation in the remission stage of ulcerative colitis using probe-based confocal laser endomicroscopy. BMC Gastroenterol 2019,19(1),114","journal-title":"BMC Gastroenterol"},{"key":"ref=131","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1023\/B:DDAS.0000037822.55717.31","volume":"49","author":"Magro F.","year":"2004","unstructured":"Magro F.; Araujo F.; Pereira P.; Meireles E.; Diniz-Ribeiro M.; Velosom F.T.; Soluble selectins, sICAM, sVCAM, and angiogenic proteins in different activity groups of patients with inflammatory bowel disease. Dig Dis Sci 2004,49(7-8),1265-1274","journal-title":"Dig Dis Sci"},{"key":"ref=132","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1007\/s00384-003-0495-y","volume":"18","author":"Kapsoritakis A.","year":"2003","unstructured":"Kapsoritakis A.; Sfiridaki A.; Maltezos E.; Vascular endothelial growth factor in inflammatory bowel disease. Int J Colorectal Dis 2003,18(5),418-422","journal-title":"Int J Colorectal Dis"},{"key":"ref=133","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2147\/HP.S219049","volume":"8","author":"deZoeten E.F.","year":"2020","unstructured":"deZoeten E.F.; Battista K.D.; Colson S.B.; Markers of hypoxia correlate with histologic and endoscopic severity of colitis in inflammatory bowel disease. Hypoxia (Auckl) 2020,8,1-12","journal-title":"Hypoxia (Auckl)"},{"key":"ref=134","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.intimp.2010.11.023","volume":"11","author":"Frysz-Naglak D.","year":"2011","unstructured":"Frysz-Naglak D.; Fryc B.; Klimacka-Nawrot E.; Expression, localization and systemic concentration of vascular endothelial growth factor (VEGF) and its receptors in patients with ulcerative colitis. Int Immunopharmacol 2011,11(2),220-225","journal-title":"Int Immunopharmacol"},{"key":"ref=135","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1111\/j.1572-0241.2001.03527.x","volume":"96","author":"Kanazawa S.","year":"2001","unstructured":"Kanazawa S.; Tsunoda T.; Onuma E.; Majima T.; Kagiyama M.; Kikuchi K.; VEGF, basic-FGF, and TGF-beta in Crohn\u2019s disease and ulcerative colitis: a novel mechanism of chronic intestinal inflammation. Am J Gastroenterol 2001,96(3),822-828","journal-title":"Am J Gastroenterol"},{"key":"ref=136","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1080\/00365529850172070","volume":"33","author":"Griga T.","year":"1998","unstructured":"Griga T.; Tromm A.; Spranger J.; May B.; Increased serum levels of vascular endothelial growth factor in patients with inflammatory bowel disease. Scand J Gastroenterol 1998,33(5),504-508","journal-title":"Scand J Gastroenterol"},{"key":"ref=137","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1590\/1516-3180.2018.0274161118","volume":"136","author":"Aksoy E.K.","year":"2018","unstructured":"Aksoy E.K.; \u00c7etinkaya H.; Sava\u015f B.; Ensari A.; Torgutalp M.; Efe C.; Vascular endothelial growth factor, endostatin levels and clinical features among patients with ulcerative colitis and irritable bowel syndrome and among healthy controls: a cross-sectional analytical study. Sao Paulo Med J 2018,136(6),543-550","journal-title":"Sao Paulo Med J"},{"key":"ref=138","first-page":"920","volume":"46","author":"Griga T.","year":"1999","unstructured":"Griga T.; Voigt E.; Gretzer B.; Brasch F.; May B.; Increased production of vascular endothelial growth factor by intestinal mucosa of patients with inflammatory bowel disease. Hepatogastroenterology 1999,46(26),920-923","journal-title":"Hepatogastroenterology"},{"key":"ref=139","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1002\/bjs.4453","volume":"91","author":"Beddy D.","year":"2004","unstructured":"Beddy D.; Watson R.W.; Fitzpatrick J.M.; O\u2019Connell P.R.; Increased vascular endothelial growth factor production in fibroblasts isolated from strictures in patients with Crohn\u2019s disease. Br J Surg 2004,91(1),72-77","journal-title":"Br J Surg"},{"key":"ref=140","doi-asserted-by":"publisher","first-page":"3863","DOI":"10.1172\/JCI72189","volume":"124","author":"D\u2019Alessio S.","year":"2014","unstructured":"D\u2019Alessio S.; Correale C.; Tacconi C.; VEGF-C-dependent stimulation of lymphatic function ameliorates experimental inflammatory bowel disease. J Clin Invest 2014,124(9),3863-3878","journal-title":"J Clin Invest"},{"key":"ref=141","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1016\/S0190-9622(96)90603-9","volume":"35","author":"Kadono T.","year":"1996","unstructured":"Kadono T.; Kikuchi K.; Kubo M.; Fujimoto M.; Tamaki K.; Serum concentrations of basic fibroblast growth factor in collagen diseases. J Am Acad Dermatol 1996,35(3 Pt 1),392-397","journal-title":"J Am Acad Dermatol"},{"key":"ref=142","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1023\/A:1018882322566","volume":"42","author":"Bousvaros A.","year":"1997","unstructured":"Bousvaros A.; Zurakowski D.; Fishman S.J.; Serum basic fibroblast growth factor in pediatric Crohn\u2019s disease. Implications for wound healing. Dig Dis Sci 1997,42(2),378-386","journal-title":"Dig Dis Sci"},{"key":"ref=143","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1007\/s000110050161","volume":"46","author":"Matsuno M.","year":"1997","unstructured":"Matsuno M.; Shiota G.; Umeki K.; Kawasaki H.; Kojo H.; Miura K.; Induction of plasma hepatocyte growth factor in acute colitis of mice. Inflamm Res 1997,46(5),166-167","journal-title":"Inflamm Res"},{"key":"ref=144","doi-asserted-by":"publisher","first-page":"2275","DOI":"10.1023\/A:1020195513193","volume":"47","author":"Ortega-Cava C.F.","year":"2002","unstructured":"Ortega-Cava C.F.; Ishihara S.; Kawashima K.; Hepatocyte growth factor expression in dextran sodium sulfate-induced colitis in rats. Dig Dis Sci 2002,47(10),2275-2285","journal-title":"Dig Dis Sci"},{"key":"ref=145","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1053\/j.gastro.2004.08.027","volume":"127","author":"Itoh H.","year":"2004","unstructured":"Itoh H.; Naganuma S.; Takeda N.; Regeneration of injured intestinal mucosa is impaired in hepatocyte growth factor activator-deficient mice. Gastroenterology 2004,127(5),1423-1435","journal-title":"Gastroenterology"},{"key":"ref=146","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1124\/jpet.103.054106","volume":"307","author":"Tahara Y.","year":"2003","unstructured":"Tahara Y.; Ido A.; Yamamoto S.; Hepatocyte growth factor facilitates colonic mucosal repair in experimental ulcerative colitis in rats. J Pharmacol Exp Ther 2003,307(1),146-151","journal-title":"J Pharmacol Exp Ther"},{"key":"ref=147","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1007\/s10620-005-2664-z","volume":"50","author":"Ohda Y.","year":"2005","unstructured":"Ohda Y.; Hori K.; Tomita T.; Effects of hepatocyte growth factor on rat inflammatory bowel disease models. Dig Dis Sci 2005,50(5),914-921","journal-title":"Dig Dis Sci"},{"key":"ref=148","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1097\/01.MIB.0000164192.71381.5c","volume":"11","author":"Numata M.","year":"2005","unstructured":"Numata M.; Ido A.; Moriuchi A.; Hepatocyte growth factor facilitates the repair of large colonic ulcers in 2,4,6-trinitrobenzene sulfonic acid-induced colitis in rats. Inflamm Bowel Dis 2005,11(6),551-558","journal-title":"Inflamm Bowel Dis"},{"key":"ref=149","doi-asserted-by":"publisher","first-page":"G729","DOI":"10.1152\/ajpgi.00438.2004","volume":"288","author":"Oh K.","year":"2005","unstructured":"Oh K.; Iimuro Y.; Takeuchi M.; Ameliorating effect of hepatocyte growth factor on inflammatory bowel disease in a murine model. Am J Physiol Gastrointest Liver Physiol 2005,288(4),G729-G735","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"ref=150","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1097\/00005176-200111000-00007","volume":"33","author":"Srivastava M.","year":"2001","unstructured":"Srivastava M.; Zurakowski D.; Cheifetz P.; Leichtner A.; Bousvaros A.; Elevated serum hepatocyte growth factor in children and young adults with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2001,33(5),548-553","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"ref=151","first-page":"25","volume":"97","author":"Matsuno M.","year":"1997","unstructured":"Matsuno M.; Shiota G.; Umeki K.; Kawasaki H.; Kojo H.; Miura K.; Clinical evaluation of hepatocyte growth factor in patients with gastrointestinal and pancreatic diseases with special reference to inflammatory bowel disease. Res Commun Mol Pathol Pharmacol 1997,97(1),25-37","journal-title":"Res Commun Mol Pathol Pharmacol"},{"key":"ref=152","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1097\/00042737-200012040-00013","volume":"12","author":"Sturm A.","year":"2000","unstructured":"Sturm A.; Schulte C.; Schatton R.; Transforming growth factor-beta and hepatocyte growth factor plasma levels in patients with inflammatory bowel disease. Eur J Gastroenterol Hepatol 2000,12(4),445-450","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"ref=153","first-page":"S245","volume":"6","author":"Eliceiri B.P.","year":"2000","unstructured":"Eliceiri B.P.; Cheresh D.A.; Role of alpha v integrins during angiogenesis. Cancer J 2000,6(Suppl. 3),S245-S249","journal-title":"Cancer J"},{"key":"ref=154","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1159\/000113790","volume":"75","author":"Punekar S.","year":"2008","unstructured":"Punekar S.; Zak S.; Kalter V.G.; Thrombospondin 1 and its mimetic peptide ABT-510 decrease angiogenesis and inflammation in a murine model of inflammatory bowel disease. Pathobiology 2008,75(1),9-21","journal-title":"Pathobiology"},{"key":"ref=155","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1007\/s00384-007-0397-5","volume":"23","author":"Zak S.","year":"2008","unstructured":"Zak S.; Treven J.; Nash N.; Gutierrez L.S.; Lack of thrombospondin-1 increases angiogenesis in a model of chronic inflammatory bowel disease. Int J Colorectal Dis 2008,23(3),297-304","journal-title":"Int J Colorectal Dis"},{"key":"ref=156","doi-asserted-by":"publisher","first-page":"3180","DOI":"10.3748\/wjg.v20.i12.3180","volume":"20","author":"Voudoukis E.","year":"2014","unstructured":"Voudoukis E.; Karmiris K.; Koutroubakis I.E.; Multipotent role of platelets in inflammatory bowel diseases: a clinical approach. World J Gastroenterol 2014,20(12),3180-3190","journal-title":"World J Gastroenterol"},{"key":"ref=157","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1136\/gut.34.2.247","volume":"34","author":"Webberley M.J.","year":"1993","unstructured":"Webberley M.J.; Hart M.T.; Melikian V.; Thromboembolism in inflammatory bowel disease: role of platelets. Gut 1993,34(2),247-251","journal-title":"Gut"},{"key":"ref=158","first-page":"469","volume":"26","author":"Ashton J.J.","year":"2020","unstructured":"Ashton J.J.; Borca F.; Mossotto E.; Phan H.T.T.; Ennis S.; Beattie R.M.; Analysis and hierarchical clustering of blood results before diagnosis in pediatric inflammatory bowel disease. Inflamm Bowel Dis 2020,26,469-475","journal-title":"Inflamm Bowel Dis"},{"key":"ref=159","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1111\/ped.13892","volume":"61","author":"Takaki Y.","year":"2019","unstructured":"Takaki Y.; Mizuochi T.; Eda K.; Ishihara J.; Yamashita Y.; Laboratory values in Japanese children with newly diagnosed inflammatory bowel disease. Pediatr Int (Roma) 2019,61(7),720-725","journal-title":"Pediatr Int (Roma)"},{"key":"ref=160","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1093\/ecco-jcc\/jjz132","volume":"14","author":"Li T.","year":"2020","unstructured":"Li T.; Wang C.; Liu Y.; Neutrophil extracellular traps induce intestinal damage and thrombotic tendency in inflammatory bowel disease. J Crohn\u2019s Colitis 2020,14(2),240-253","journal-title":"J Crohn\u2019s Colitis"},{"key":"ref=161","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1016\/j.crohns.2013.11.001","volume":"8","author":"Schmid W.","year":"2014","unstructured":"Schmid W.; Vogelsang H.; Papay P.; Increased responsiveness to thrombin through protease-activated receptors (PAR)-1 and -4 in active Crohn\u2019s disease. J Crohn\u2019s Colitis 2014,8(6),495-503","journal-title":"J Crohn\u2019s Colitis"},{"key":"ref=162","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1159\/000065082","volume":"32","author":"Larsen T.B.","year":"2002","unstructured":"Larsen T.B.; Nielsen J.N.; Fredholm L.; Platelets and anticoagulant capacity in patients with inflammatory bowel disease. Pathophysiol Haemost Thromb 2002,32(2),92-96","journal-title":"Pathophysiol Haemost Thromb"},{"key":"ref=163","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1007\/s00535-005-1721-x","volume":"41","author":"Andoh A.","year":"2006","unstructured":"Andoh A.; Yoshida T.; Yagi Y.; Increased aggregation response of platelets in patients with inflammatory bowel disease. J Gastroenterol 2006,41(1),47-54","journal-title":"J Gastroenterol"},{"key":"ref=164","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.ajpath.2013.03.014","volume":"183","author":"Senchenkova E.Y.","year":"2013","unstructured":"Senchenkova E.Y.; Komoto S.; Russell J.; Interleukin-6 mediates the platelet abnormalities and thrombogenesis associated with experimental colitis. Am J Pathol 2013,183(1),173-181","journal-title":"Am J Pathol"},{"key":"ref=165","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1097\/01.MIB.0000440614.83703.84","volume":"20","author":"Yan S.L.","year":"2014","unstructured":"Yan S.L.; Russell J.; Granger D.N.; Platelet activation and platelet-leukocyte aggregation elicited in experimental colitis are mediated by interleukin-6. Inflamm Bowel Dis 2014,20(2),353-362","journal-title":"Inflamm Bowel Dis"},{"key":"ref=166","doi-asserted-by":"publisher","first-page":"119","DOI":"10.5603\/FHC.2011.0017","volume":"49","author":"Poli\u0144ska B.","year":"2011","unstructured":"Poli\u0144ska B.; Matowicka-Karna J.; Kemona H.; Assessment of the influence of the inflammatory process on the activation of blood platelets and morphological parameters in patients with ulcerative colitis (colitis ulcerosa). Folia Histochem Cytobiol 2011,49(1),119-124","journal-title":"Folia Histochem Cytobiol"},{"key":"ref=167","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1089\/107999099313604","volume":"19","author":"Heits F.","year":"1999","unstructured":"Heits F.; Stahl M.; Ludwig D.; Stange E.F.; Jelkmann W.; Elevated serum thrombopoietin and interleukin-6 concentrations in thrombocytosis associated with inflammatory bowel disease. J Interferon Cytokine Res 1999,19(7),757-760","journal-title":"J Interferon Cytokine Res"},{"key":"ref=168","doi-asserted-by":"publisher","first-page":"68108","DOI":"10.18632\/oncotarget.19202","volume":"8","author":"Gawro\u0144ska B.","year":"2017","unstructured":"Gawro\u0144ska B.; Matowicka-Karna J.; Kralisz M.; Kemona H.; Markers of inflammation and influence of nitric oxide on platelet activation in the course of ulcerative colitis. Oncotarget 2017,8(40),68108-68114","journal-title":"Oncotarget"},{"key":"ref=169","doi-asserted-by":"publisher","first-page":"101","DOI":"10.3389\/fimmu.2014.00101","volume":"5","author":"Petrey A.C.","year":"2014","unstructured":"Petrey A.C.; de la Motte C.A.; Hyaluronan, a crucial regulator of inflammation. Front Immunol 2014,5,101","journal-title":"Front Immunol"},{"key":"ref=170","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1182\/blood-2014-07-590513","volume":"125","author":"Albeiroti S.","year":"2015","unstructured":"Albeiroti S.; Ayasoufi K.; Hill D.R.; Shen B.; de la Motte C.A.; Platelet hyaluronidase-2: an enzyme that translocates to the surface upon activation to function in extracellular matrix degradation. Blood 2015,125(9),1460-1469","journal-title":"Blood"},{"key":"ref=171","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1182\/blood.2018893594","volume":"134","author":"Petrey A.C.","year":"2019","unstructured":"Petrey A.C.; Obery D.R.; Kessler S.P.; Zawerton A.; Flamion B.; de la Motte C.A.; Platelet hyaluronidase-2 regulates the early stages of inflammatory disease in colitis. Blood 2019,134(9),765-775","journal-title":"Blood"},{"key":"ref=172","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/S0002-9270(00)02325-X","volume":"96","author":"van Bodegraven A.A.","year":"2001","unstructured":"van Bodegraven A.A.; Schoorl M.; Baak J.P.; Linskens R.K.; Bartels P.C.; Tuynman H.A.; Hemostatic imbalance in active and quiescent ulcerative colitis. Am J Gastroenterol 2001,96(2),487-493","journal-title":"Am J Gastroenterol"},{"key":"ref=173","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1080\/00365529850171927","volume":"33","author":"Kjeldsen J.","year":"1998","unstructured":"Kjeldsen J.; Lassen J.F.; Brandslund I.; Schaffalitzky de Muckadell O.B.; Markers of coagulation and fibrinolysis as measures of disease activity in inflammatory bowel disease. Scand J Gastroenterol 1998,33(6),637-643","journal-title":"Scand J Gastroenterol"},{"key":"ref=174","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1097\/00005176-199904000-00013","volume":"28","author":"Weber P.","year":"1999","unstructured":"Weber P.; Husemann S.; Vielhaber H.; Zimmer K.P.; Nowak-G\u00f6ttl U.; Coagulation and fibrinolysis in children, adolescents, and young adults with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 1999,28(4),418-422","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"ref=175","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1159\/000073850","volume":"33","author":"Vrij A.A.","year":"2003","unstructured":"Vrij A.A.; Rijken J.; van Wersch J.W.; Stockbr\u00fcgger R.W.; Coagulation and fibrinolysis in inflammatory bowel disease and in giant cell arteritis. Pathophysiol Haemost Thromb 2003,33(2),75-83","journal-title":"Pathophysiol Haemost Thromb"},{"key":"ref=176","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1136\/jcp.36.12.1387","volume":"36","author":"Knot E.","year":"1983","unstructured":"Knot E.; Ten Cate J.W.; Leeksma O.C.; Tytgat G.N.; Vreeken J.; No evidence for a prethrombotic state in stable chronic inflammatory bowel disease. J Clin Pathol 1983,36(12),1387-1390","journal-title":"J Clin Pathol"},{"key":"ref=177","doi-asserted-by":"publisher","first-page":"659","DOI":"10.2174\/157016112801784495","volume":"10","author":"Stadnicki A.","year":"2012","unstructured":"Stadnicki A.; Involvement of coagulation and hemostasis in inflammatory bowel diseases. Curr Vasc Pharmacol 2012,10(5),659-669","journal-title":"Curr Vasc Pharmacol"},{"key":"ref=178","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1007\/s11239-006-9032-5","volume":"22","author":"Yilmaz S.","year":"2006","unstructured":"Yilmaz S.; Bayan K.; T\u00fcz\u00fcn Y.; Batun S.; Altinta\u015f A.; A comprehensive analysis of 12 thrombophilic mutations and related parameters in patients with inflammatory bowel disease: data from Turkey. J Thromb Thrombolysis 2006,22(3),205-212","journal-title":"J Thromb Thrombolysis"},{"key":"ref=179","doi-asserted-by":"publisher","first-page":"30056","DOI":"10.1016\/j.cgh.2019.12.043","volume":"S1542-3565","author":"Lagrange J","year":"2020","unstructured":"Lagrange J; Lacolley P; Wahl D; Peyrin-Biroulet L; Regnault V; Shedding light on hemostasis in patients with inflammatory bowel diseases. Clin. Gastroenterol Hepatol2020,S1542-3565(20),30056-2"},{"key":"ref=180","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1016\/j.thromres.2009.10.012","volume":"125","author":"Saibeni S.","year":"2010","unstructured":"Saibeni S.; Saladino V.; Chantarangkul V.; Increased thrombin generation in inflammatory bowel diseases. Thromb Res 2010,125(3),278-282","journal-title":"Thromb Res"},{"key":"ref=181","first-page":"1221","volume":"91","author":"Smith C.J.","year":"1996","unstructured":"Smith C.J.; Haire W.D.; Kaufman S.S.; Mack D.R.; Determination of prothrombin activation fragments in young patients with inflammatory bowel disease. Am J Gastroenterol 1996,91(6),1221-1225","journal-title":"Am J Gastroenterol"},{"key":"ref=182","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1097\/00042737-199512000-00010","volume":"7","author":"Chamouard P.","year":"1995","unstructured":"Chamouard P.; Grunebaum L.; Wiesel M.L.; Prothrombin fragment 1 + 2 and thrombin-antithrombin III complex as markers of activation of blood coagulation in inflammatory bowel diseases. Eur J Gastroenterol Hepatol 1995,7(12),1183-1188","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"ref=183","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1177\/1076029611405034","volume":"17","author":"Alkim H.","year":"2011","unstructured":"Alkim H.; Ayaz S.; Alkim C.; Ulker A.; Sahin B.; Continuous active state of coagulation system in patients with nonthrombotic inflammatory bowel disease. Clin Appl Thromb Hemost 2011,17(6),600-604","journal-title":"Clin Appl Thromb Hemost"},{"key":"ref=184","doi-asserted-by":"publisher","first-page":"253","DOI":"10.20452\/pamw.4481","volume":"129","author":"Cibor D.","year":"2019","unstructured":"Cibor D.; Szczeklik K.; Mach T.; Owczarek D.; Levels of tissue factor pathway inhibitor in patients with inflammatory bowel disease. Pol Arch Intern Med 2019,129(4),253-258","journal-title":"Pol Arch Intern Med"},{"key":"ref=185","doi-asserted-by":"publisher","first-page":"287","DOI":"10.3109\/00365521.2013.870597","volume":"49","author":"Kohoutova D.","year":"2014","unstructured":"Kohoutova D.; Pecka M.; Cihak M.; Cyrany J.; Maly J.; Bures J.; Prevalence of hypercoagulable disorders in inflammatory bowel disease. Scand J Gastroenterol 2014,49(3),287-294","journal-title":"Scand J Gastroenterol"},{"key":"ref=186","doi-asserted-by":"publisher","first-page":"2333","DOI":"10.1002\/ibd.21631","volume":"17","author":"Bernhard H.","year":"2011","unstructured":"Bernhard H.; Deutschmann A.; Leschnik B.; Thrombin generation in pediatric patients with Crohn\u2019s disease. Inflamm Bowel Dis 2011,17(11),2333-2339","journal-title":"Inflamm Bowel Dis"},{"key":"ref=187","doi-asserted-by":"publisher","first-page":"7461","DOI":"10.3748\/wjg.v20.i23.7461","volume":"20","author":"He H.L.","year":"2014","unstructured":"He H.L.; Zhang J.B.; Li Q.; Clinical significance of expression of tissue factor and tissue factor pathway inhibitor in ulcerative colitis. World J Gastroenterol 2014,20(23),7461","journal-title":"World J Gastroenterol"},{"key":"ref=188","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1016\/j.prp.2012.06.005","volume":"208","author":"Reichman-Warmusz E.","year":"2012","unstructured":"Reichman-Warmusz E.; Kurek J.; Gabriel A.; Tissue hemostasis and chronic inflammation in colon biopsies of patients with inflammatory bowel disease. Pathol Res Pract 2012,208(9),553-556","journal-title":"Pathol Res Pract"},{"key":"ref=189","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1080\/00365529950173708","volume":"34","author":"Meucci G.","year":"1999","unstructured":"Meucci G.; Pareti F.; Vecchi M.; Saibeni S.; Bressi C.; de Franchis R.; Serum von Willebrand factor levels in patients with inflammatory bowel disease are related to systemic inflammation. Scand J Gastroenterol 1999,34(3),287-290","journal-title":"Scand J Gastroenterol"},{"key":"ref=190","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1007\/BF02208650","volume":"40","author":"Souto J.C.","year":"1995","unstructured":"Souto J.C.; Mart\u00ednez E.; Roca M.; Prothrombotic state and signs of endothelial lesion in plasma of patients with inflammatory bowel disease. Dig Dis Sci 1995,40(9),1883-1889","journal-title":"Dig Dis Sci"},{"key":"ref=191","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1055\/s-0038-1645068","volume":"63","author":"Gris J.C.","year":"1990","unstructured":"Gris J.C.; Schved J.F.; Raffanel C.; Impaired fibrinolytic capacity in patients with inflammatory bowel disease. Thromb Haemost 1990,63(3),472-475","journal-title":"Thromb Haemost"},{"key":"ref=192","doi-asserted-by":"publisher","first-page":"1510","DOI":"10.1111\/j.1538-7836.2006.01970.x","volume":"4","author":"Saibeni S.","year":"2006","unstructured":"Saibeni S.; Ciscato C.; Vecchi M.; Antibodies to tissue-type plasminogen activator (t-PA) in patients with inflammatory bowel disease: high prevalence, interactions with functional domains of t-PA and possible implications in thrombosis. J Thromb Haemost 2006,4(7),1510-1516","journal-title":"J Thromb Haemost"},{"key":"ref=193","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1097\/MEG.0b013e3282faa759","volume":"20","author":"Koutroubakis I.E.","year":"2008","unstructured":"Koutroubakis I.E.; Sfiridaki A.; Tsiolakidou G.; Coucoutsi C.; Theodoropoulou A.; Kouroumalis E.A.; Plasma thrombin-activatable fibrinolysis inhibitor and plasminogen activator inhibitor-1 levels in inflammatory bowel disease. Eur J Gastroenterol Hepatol 2008,20(9),912-916","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"ref=194","doi-asserted-by":"publisher","first-page":"2616","DOI":"10.1097\/01.MIB.0000437041.59208.44","volume":"19","author":"Owczarek D.","year":"2013","unstructured":"Owczarek D.; Cibor D.; Sa\u0142apa K.; G\u0142owacki M.K.; Mach T.; Undas A.; Reduced plasma fibrin clot permeability and susceptibility to lysis in patients with inflammatory bowel disease: a novel prothrombotic mechanism. Inflamm Bowel Dis 2013,19(12),2616-2624","journal-title":"Inflamm Bowel Dis"},{"key":"ref=195","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1016\/S0140-6736(89)91078-7","volume":"2","author":"Wakefield A.J.","year":"1989","unstructured":"Wakefield A.J.; Sawyerr A.M.; Dhillon A.P.; Pathogenesis of Crohn\u2019s disease: multifocal gastrointestinal infarction. Lancet 1989,2(8671),1057-1062","journal-title":"Lancet"},{"key":"ref=196","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1055\/s-0038-1650653","volume":"76","author":"Stouthard J.M.","year":"1996","unstructured":"Stouthard J.M.; Levi M.; Hack C.E.; Interleukin-6 stimulates coagulation, not fibrinolysis, in humans. Thromb Haemost 1996,76(5),738-742","journal-title":"Thromb Haemost"},{"key":"ref=197","doi-asserted-by":"publisher","first-page":"2774","DOI":"10.2353\/ajpath.2010.100205","volume":"177","author":"Yoshida H.","year":"2010","unstructured":"Yoshida H.; Russell J.; Senchenkova E.Y.; Almeida Paula L.D.; Granger D.N.; Interleukin-1beta mediates the extra-intestinal thrombosis associated with experimental colitis. Am J Pathol 2010,177(6),2774-2781","journal-title":"Am J Pathol"},{"key":"ref=198","doi-asserted-by":"publisher","first-page":"2217","DOI":"10.1002\/ibd.21593","volume":"17","author":"Yoshida H.","year":"2011","unstructured":"Yoshida H.; Yilmaz C.E.; Granger D.N.; Role of tumor necrosis factor-\u03b1 in the extraintestinal thrombosis associated with colonic inflammation. Inflamm Bowel Dis 2011,17(11),2217-2223","journal-title":"Inflamm Bowel Dis"},{"key":"ref=199","doi-asserted-by":"publisher","first-page":"201","DOI":"10.3349\/ymj.2006.47.2.201","volume":"47","author":"Song J.W.","year":"2006","unstructured":"Song J.W.; Song K.S.; Choi J.R.; Kim S.Y.; Rhee J.H.; Plasma level of IL-6 and its relationship to procoagulant and fibrinolytic markers in acute ischemic stroke. Yonsei Med J 2006,47(2),201-206","journal-title":"Yonsei Med J"},{"key":"ref=200","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1097\/MIB.0000000000000656","volume":"22","author":"Hozumi H.","year":"2016","unstructured":"Hozumi H.; Russell J.; Vital S.; Granger D.N.; IL-6 mediates the intestinal microvascular thrombosis associated with experimental colitis. Inflamm Bowel Dis 2016,22(3),560-568","journal-title":"Inflamm Bowel Dis"},{"key":"ref=201","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1080\/08923973.2018.1469144","volume":"40","author":"Hvas C.L.","year":"2018","unstructured":"Hvas C.L.; Bendix M.; Dige A.; Dahlerup J.F.; Agnholt J.; Current, experimental, and future treatments in inflammatory bowel disease: a clinical review. Immunopharmacol Immunotoxicol 2018,40(6),446-460","journal-title":"Immunopharmacol Immunotoxicol"},{"key":"ref=202","doi-asserted-by":"publisher","first-page":"395","DOI":"10.3892\/etm.2016.3966","volume":"13","author":"Wu P.","year":"2017","unstructured":"Wu P.; Jia F.; Zhang B.; Zhang P.; Risk of cardiovascular disease in inflammatory bowel disease. Exp Ther Med 2017,13(2),395-400","journal-title":"Exp Ther Med"},{"key":"ref=203","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1093\/ecco-jcc\/jjv213","volume":"10","author":"Harbord M.","year":"2016","unstructured":"Harbord M.; Annese V.; Vavricka S.R.; European Crohn\u2019s and Colitis Organisation. The first european evidence-based consensus on extra-intestinal manifestations in inflammatory bowel disease. J Crohn\u2019s Colitis 2016,10(3),239-254","journal-title":"J Crohn\u2019s Colitis"},{"key":"ref=204","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.jcol.2016.03.003","volume":"36","author":"Moura R.M.","year":"2016","unstructured":"Moura R.M.; Hartmann R.M.; Licks F.; Antioxidant effect of mesalazine in the experimental colitis model induced by acetic acid. J Coloproctol (Rio J) 2016,36,139-148","journal-title":"J Coloproctol (Rio J)"},{"key":"ref=205","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1136\/gutjnl-2012-303285","volume":"62","author":"Rungoe C.","year":"2013","unstructured":"Rungoe C.; Basit S.; Ranthe M.F.; Wohlfahrt J.; Langholz E.; Jess T.; Risk of ischaemic heart disease in patients with inflammatory bowel disease: a nationwide Danish cohort study. Gut 2013,62(5),689-694","journal-title":"Gut"},{"key":"ref=206","doi-asserted-by":"publisher","first-page":"4370","DOI":"10.4049\/jimmunol.1302527","volume":"192","author":"Marinkovi\u0107 G.","year":"2014","unstructured":"Marinkovi\u0107 G.; Kroon J.; Hoogenboezem M.; Inhibition of GTPase Rac1 in endothelium by 6-mercaptopurine results in immunosuppression in nonimmune cells: new target for an old drug. J Immunol 2014,192(9),4370-4378","journal-title":"J Immunol"},{"key":"ref=207","doi-asserted-by":"publisher","first-page":"2380","DOI":"10.1161\/ATVBAHA.113.301394","volume":"33","author":"Marinkovic G.","year":"2013","unstructured":"Marinkovic G.; Hibender S.; Hoogenboezem M.; Immunosuppressive drug azathioprine reduces aneurysm progression through inhibition of Rac1 and c-Jun-terminal-N-kinase in endothelial cells. Arterioscler Thromb Vasc Biol 2013,33(10),2380-2388","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"ref=208","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.12659\/MSM.893865","volume":"21","author":"dos Santos L.C.","year":"2015","unstructured":"dos Santos L.C.; Costa A.V.; Lopes L.G.; Combination of azathioprine and aminosalicylate treatment prevent risk of cardiovascular disease in women with ul-cerative colitis by reducing inflammation. Med Sci Monit 2015,21,2305-2315","journal-title":"Med Sci Monit"},{"key":"ref=209","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1016\/j.jbspin.2014.01.014","volume":"81","author":"Prati C.","year":"2014","unstructured":"Prati C.; Demougeot C.; Guillot X.; Godfrin-Valnet M.; Wendling D.; Endothelial dysfunction in joint disease. Joint Bone Spine 2014,81(5),386-391","journal-title":"Joint Bone Spine"},{"key":"ref=210","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1136\/annrheumdis-2014-206305","volume":"75","author":"Thornton C.C.","year":"2016","unstructured":"Thornton C.C.; Al-Rashed F.; Calay D.; Methotrexate-mediated activation of an AMPK-CREB-dependent pathway: a novel mechanism for vascular protection in chronic systemic inflammation. Ann Rheum Dis 2016,75(2),439-448","journal-title":"Ann Rheum Dis"},{"key":"ref=211","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1016\/S0022-2143(96)90153-5","volume":"127","author":"Bombeli T.","year":"1996","unstructured":"Bombeli T.; M\u00fcller M.; Straub P.W.; Haeberli A.; Cyclosporine-induced detachment of vascular endothelial cells initiates the intrinsic coagulation system in plasma and whole blood. J Lab Clin Med 1996,127(6),621-634","journal-title":"J Lab Clin Med"},{"key":"ref=212","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1053\/j.gastro.2008.09.064","volume":"136","author":"Scaldaferri F.","year":"2009","unstructured":"Scaldaferri F.; Vetrano S.; Sans M.; VEGF-A links angiogenesis and inflammation in inflammatory bowel disease pathogenesis. Gastroenterology 2009,136,585-595","journal-title":"Gastroenterology"},{"key":"ref=213","doi-asserted-by":"publisher","first-page":"2617","DOI":"10.4049\/jimmunol.176.4.2617","volume":"176","author":"Danese S.","year":"2006","unstructured":"Danese S.; Sans M.; Scaldaferri F.; TNF-alpha blockade down-regulates the CD40\/CD40L pathway in the mucosal microcirculation: a novel anti-inflammatory mechanism of infliximab in Crohn\u2019s disease. J Immunol 2006,176(4),2617-2624","journal-title":"J Immunol"},{"key":"ref=214","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1053\/j.gastro.2014.08.044","volume":"147","author":"Danese S.","year":"2014","unstructured":"Danese S.; Pan\u00e9s J.; Development of drugs to target interactions between leukocytes and endothelial cells and treatment algorithms for in-flammatory bowel diseases. Gastroenterology 2014,147,981-989","journal-title":"Gastroenterology"},{"key":"ref=215","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s11894-015-0444-2","volume":"17","author":"L\u00f6wenberg M.","year":"2015","unstructured":"L\u00f6wenberg M.; D\u2019Haens G.; Next-Generation Therapeutics for IBD. Curr Gastroenterol Rep 2015,17(6),21","journal-title":"Curr Gastroenterol Rep"},{"key":"ref=216","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.jaut.2017.07.004","volume":"85","author":"Argollo M.","year":"2017","unstructured":"Argollo M.; Fiorino G.; Hindryckx P.; Peyrin-Biroulet L.; Danese S.; Novel therapeutic targets for inflammatory bowel disease. J Autoimmun 2017,85,103-116","journal-title":"J Autoimmun"},{"key":"ref=217","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.csbj.2019.01.001","volume":"17","author":"Grenier L.","year":"2019","unstructured":"Grenier L.; Hu P.; Computational drug repurposing for inflammatory bowel disease using genetic information. Comput Struct Biotechnol J 2019,17,127-135","journal-title":"Comput Struct Biotechnol J"},{"key":"ref=218","doi-asserted-by":"crossref","first-page":"2562","DOI":"10.1097\/MIB.0000000000000912","volume":"22","author":"Collij V.","year":"2016","unstructured":"Collij V.; Festen E.A.; Alberts R.; Weersma R.K.; Drug repositioning in inflammatory bowel disease based on genetic information. Inflamm Bowel Dis 2016,22,2562-2570","journal-title":"Inflamm Bowel Dis"},{"key":"ref=219","doi-asserted-by":"publisher","first-page":"9386","DOI":"10.1038\/s41598-019-45747-2","volume":"9","author":"Mokry L.E.","year":"2019","unstructured":"Mokry L.E.; Zhou S.; Guo C.; Interleukin-18 as a drug repositioning opportunity for inflammatory bowel disease: A Mendelian randomization study. Sci Rep 2019,9(1),9386","journal-title":"Sci Rep"},{"key":"ref=220","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1093\/cvr\/cvs220","volume":"96","author":"Elhage R.","year":"2012","unstructured":"Elhage R.; Ljunggren H-G.; Hansson G.K.; Proatherogenic role of interleukin-18: effects on inflammation and action on vascular cells: AUTHORS\u2019 RETROSPECTIVE. Cardiovasc Res 2012,96,176-180","journal-title":"Cardiovasc Res"}],"container-title":["Current Pharmaceutical Design"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/eurekaselect.com\/article\/download\/183375","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,31]],"date-time":"2022-10-31T18:15:18Z","timestamp":1667240118000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/183375\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,4]]},"references-count":220,"journal-issue":{"issue":"30","published-print":{"date-parts":[[2020,9,4]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1381612826666200701212414","relation":{},"ISSN":["1381-6128"],"issn-type":[{"type":"print","value":"1381-6128"}],"subject":[],"published":{"date-parts":[[2020,9,4]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2020-02-14","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-06-04","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-09-04","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}